ELSEVIER

Clinica Chimica Acta 240 (1995) 225–227

Author index

Volume 240 (1995)

Åkesson, B., see Persson-Moschos, M. **240**, 209
Alfi, O., see Xu, Y.-K. **240**, 21
Alldersea, J., see Duncan, H. **240**, 53
Almog, S., see Rotenberg, M. **240**, 107
Arai, H., see Sato, T. **240**, 1
Arai, T., see Kayashima, S. **240**, 11
Assogba, U., see Persson-Moschos, M. **240**, 209

Baranyai, Zs., see Sulyok, E. **240**, 155
Berry, S.A., see Röschinger, W. **240**, 35
Bonnefont-Rousselot, D., see Persson-Moschos, M. **240**, 209
Bourgeron, T., see Chretien, D. **240**, 129
Brannigan, K., see Duncan, H. **240**, 53
Bruckert, E., see Persson-Moschos, M. **240**, 209

Calvin, J., see Plumpton, T.A. **240**, 137
Cawston, T.E., see Plumpton, T.A. **240**, 137
Chappey, B., see Myara, I. **240**, 221
Chiesa, G., see Gaw, A. **240**, 75
Chretien, D., M. Pourrier, T. Bourgeron, M. Séné, A. Rötig, A. Munnich, P. Rustin, An improved spectrophotometric assay of pyruvate dehydrogenase in lactate dehydrogenase contaminated mitochondrial preparations from human skeletal muscle **240**, 129
Clark, I.M., see Plumpton, T.A. **240**, 137
Cohen, N., see Golik, A. **240**, 89
Cotariu, D., see Golik, A. **240**, 89

Delattre, J., see Persson-Moschos, M. **240**, 209
Demuth, K., see Myara, I. **240**, 221
Donnell, G.N., see Xu, Y.-K. **240**, 21
Duncan, H., C. Swan, J. Green, P. Jones, K. Brannigan, J. Alldersea, A.A. Fryer, R.C. Strange, Susceptibility to ulcerative colitis and Crohn's disease: interactions between glutathione *S*-transferase GSTM1 and GSTT1 genotypes **240**, 53

Evans, S., see Golik, A. **240**, 89

Fryer, A.A., see Duncan, H. **240**, 53
Fukasawa, M., see Sato, T. **240**, 1

Gage, D.A., see Röschinger, W. **240**, 35
Gaillard, M.C., E. Song, C.M. Nogueira, T.A. Kilroe-Smith, Elastase binding capacity of α_2-macroglobulin and its association with glucocorticoid concentration in southern African black patients with hepatocellular carcinoma **240**, 179
Gaw, A., G. Chiesa, Characterization of commercial antibodies for use in high resolution apo(a) phenotyping by immunoblot analysis **240**, 75
Giroud, J.P., see Regnault, C. **240**, 117
Giudici, T., see Xu, Y.-K. **240**, 21
Golik, A., J. Weissgarten, S. Evans, N. Cohen, R. Zaidenstein, D. Modai, D. Cotariu, Changes in red blood cell glutathione and glutathione-dependent enzymes on long-term treatment with captopril and enalapril **240**, 89
Green, J., see Duncan, H. **240**, 53
Guignard, J.-P., see Sulyok, E. **240**, 155

Haberland, M.E., see Myara, I. **240**, 221
Hazebroucq, G., see Regnault, C. **240**, 117
Huang, Z.-H., see Röschinger, W. **240**, 35

0009-8981/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved

Inoue, K., see Sato, T. **240**, 1
Ito, N., see Kayashima, S. **240**, 11
Iwamoto, T., see Röschinger, W. **240**, 35
Iwasaki, Y., see Sato, T. **240**, 1

James, I.T., see Walne, A.J. **240**, 95
Jansen, H.M., see Schoonbrood, D.F.M. **240**, 163
Jarkowska-Kozłowska, J., Z. Kozłowski, Tartrate resistant acid phosphatase in the serum of patients with larynx carcinoma — a marker of osteoclast activation **240**, 213
Jaudon, M.C., see Persson-Moschos, M. **240**, 209
Johnston, K., see Röschinger, W. **240**, 35
Jones, P., see Duncan, H. **240**, 53

Kanamori, K., see Shiba, K. **240**, 83
Kaneyoshi, A., see Kayashima, S. **240**, 11
Kaufman, F.R., see Xu, Y.-K. **240**, 21
Kayashima, S., T. Arai, M. Noritake, N. Nagata, M. Kikuchi, N. Ito, Y. Matsumoto, A. Kaneyoshi, J. Kimura, T. Kuriyama, New transcutaneous sampling of glucose for patients with type II diabetes using an ion-sensitive field-effect transistor **240**, 11
Kikuchi, M., see Kayashima, S. **240**, 11
Kilroe-Smith, T.A., see Gaillard, M.C. **240**, 179
Kimura, J., see Kayashima, S. **240**, 11
Kinoshita, M., see Sato, T. **240**, 1
Konings, C.H., Ph. Scheltens, M.A. Kuiper, E.Ch. Wolters, No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease **240**, 99
Kozłowski, Z., see Jarkowska-Kozłowska, J. **240**, 213
Kuiper, M.A., see Konings, C.H. **240**, 99
Kuriyama, T., see Kayashima, S. **240**, 11

Lutter, R., see Schoonbrood, D.F.M. **240**, 163

Matsumoto, Y., see Kayashima, S. **240**, 11
Millington, D.S., see Röschinger, W. **240**, 35
Moatti, N., see Myara, I. **240**, 221
Modai, D., see Golik, A. **240**, 89
Munnich, A., see Chretien, D. **240**, 129
Myara, I., M.E. Haberland, K. Demuth, B. Chappey, N. Moatti, Susceptibility to copper oxidation of neuraminidase-treated LDL **240**, 221

Nagata, N., see Kayashima, S. **240**, 11
Nagy, L., see Sulyok, E. **240**, 155
Naraki, T., see Sato, T. **240**, 1
Ng, W.G., see Xu, Y.-K. **240**, 21
Nogueira, C.M., see Gaillard, M.C. **240**, 179
Noritake, M., see Kayashima, S. **240**, 11

Out, T.A., see Schoonbrood, D.F.M. **240**, 163

Packman, S., see Röschinger, W. **240**, 35
Patel, D., C.P. Rubbi, D. Rickwood, Separation of T and B lymphocytes from human peripheral blood mononuclear cells using density perturbation methods **240**, 187
Perrett, D., see Walne, A.J. **240**, 95
Persson-Moschos, M., D. Bonnefont-Rousselot, U. Assogba, E. Bruckert, M.C. Jaudon, J. Delattre, B. Åkesson, Preferential depletion of selenoprotein P in hypercholesterolaemic patients treated by LDL-apheresis **240**, 209
Plumpton, C., see Plumpton, T.A. **240**, 137
Plumpton, T.A., I.M. Clark, C. Plumpton, J. Calvin, T.E. Cawston, Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (Free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP 1 and CRP in serum **240**, 137
Postaire, E., see Regnault, C. **240**, 117
Pourrier, M., see Chretien, D. **240**, 129

Regnault, C., M. Roch-Arveiller, M. Tissot, G. Sarfati, J.P. Giroud, E. Postaire, G. Hazebroucq, Effect of encapsulation on the anti-inflammatory properties of superoxide dismutase after oral administration **240**, 117
Reimert, C.M., see Schoonbrood, D.F.M. **240**, 163
Rickwood, D., see Patel, D. **240**, 187
Roch-Arveiller, M., see Regnault, C. **240**, 117
Röschinger, W., D.S. Millington, D.A. Gage, Z.-H. Huang, T. Iwamoto, S. Yano, S. Packman, K. Johnston, S.A. Berry, L. Sweetman, 3-Hydroxyisovalerylcarnitine in patients with deficiency of 3-methylcrotonyl CoA carboxylase **240**, 35
Rotenberg, M., S. Almog, Evaluation of the decarbamylation process of cholinesterase during assay of enzyme activity **240**, 107
Rötig, A., see Chretien, D. **240**, 129
Rubbi, C.P., see Patel, D. **240**, 187
Rustin, P., see Chretien, D. **240**, 129

Saeki, T., see Sato, T. **240**, 1
Saito, Y., see Sato, T. **240**, 1
Sarfati, G., see Regnault, C. **240**, 117
Sato, T., M. Fukasawa, M. Kinoshita, H. Arai,

T. Saeki, T. Naraki, Y. Iwasaki, T. Teramoto, K. Takahashi, Y. Saito, K. Inoue, Enzyme-linked immunosorbent assay for cholesteryl ester transfer protein in human serum **240**, 1
Scheltens, Ph., see Konings, C.H. **240**, 99
Schoonbrood, D.F.M., T.A. Out, R. Lutter, C.M. Reimert, F.J. van Overveld, H.M. Jansen, Plasma protein leakage and local secretion of proteins assessed in sputum in asthma and COPD. The effect of inhaled corticosteroids **240**, 163
Séné, M., see Chretien, D. **240**, 129
Shephard, M.D.S., see Tallis, G.A. **240**, 63
Shiba, K., K. Kanamori, K. Sugiura, Screening urine protein abnormalities by a novel test paper **240**, 83
Sobecki, S., see Tallis, G.A. **240**, 63
Song, E., see Gaillard, M.C. **240**, 179
Strange, R.C., see Duncan, H. **240**, 53
Sugiura, K., see Shiba, K. **240**, 83
Sulyok, E., L. Nagy, Zs. Baranyai, M. Thonney, J.-P. Guignard, Comparison of 5-hydroxyindole-acetic acid and *para*-amino hippurate clearances in newborn rabbits **240**, 155
Swan, C., see Duncan, H. **240**, 53
Sweetman, L., see Röschinger, W. **240**, 35

Takahashi, K., see Sato, T. **240**, 1
Tallis, G.A., M.D.S. Shephard, S. Sobecki, M.J. Whiting, The total apolipoprotein B/LDL-cholesterol ratio does not predict LDL particle size **240**, 63
Teramoto, T., see Sato, T. **240**, 1
Thonney, M., see Sulyok, E. **240**, 155
Tissot, M., see Regnault, C. **240**, 117

van Overveld, F.J., see Schoonbrood, D.F.M. **240**, 163

Walne, A.J., I.T. James, D. Perrett, The stability of pyridinium crosslinks in urine and serum **240**, 95
Weissgarten, J., see Golik, A. **240**, 89
Whiting, M.J., see Tallis, G.A. **240**, 63
Wolters, E.Ch., see Konings, C.H. **240**, 99

Xu, Y.-K., F.R. Kaufman, G.N. Donnell, T. Giudici, O. Alfi, W.G. Ng, HPLC analysis of uridine diphosphate sugars: decreased concentrations of uridine diphosphate galactose in erythrocytes and cultured skin fibroblasts from classical galactosemia patients **240**, 21

Yano, S., see Röschinger, W. **240**, 35

Zaidenstein, R., see Golik, A. **240**, 89

ELSEVIER

Clinica Chimica Acta 240 (1995) 229–232

Subject index

Volume 240 (1995)

Acute phase proteins; Tissue inhibitor of metalloproteinase-1; Matrix metalloproteinases; Enzyme-linked immunosorbent assay; monoclonal antibody **240**, 137

Acylcarnitine; 3-Methylcrotonyl CoA carboxylase; 3-Hydroxyisovalerylcarnitine **240**, 35

Alzheimer's disease; Monoamine oxidase **240**, 99

Anti-inflammatory properties; Superoxide dismutase; Liposomes; Ceramides; Bioavailability **240**, 117

Apolipoprotein B; Small dense low density lipoprotein particle; LDL Pattern B; Coronary heart disease **240**, 63

Apolipoprotein(a); Lipoprotein(a); Phenotyping; Monoclonal; Immunoblotting **240**, 75

Asthma; COPD; Eosinophil cationic protein; Inhaled glucocorticosteroids; Local secretion; Myeloperoxidase; Plasma protein leakage; Sputum; Tryptase **240**, 163

B cells; Cell separation; Density perturbation; Lymphocytes; Peripheral blood mononuclear cells; T cells **240**, 187

Bio-sensor; Glucose monitoring; Interstitial fluid; Type II diabetes **240**, 11

Bioavallability; Superoxide dismutase; Liposomes; Ceramides; Anti-inflammatory properties **240**, 117

Bone osteolysis; Tartrate resistant acid phosphatase; Larynx carcinoma; Osteoclasts; Macrophages **240**, 213

Captopril; Enalapril; Hypertension; Red blood cells; Glutathione; Glutathione-dependent enzymes; Lipid peroxidation **240**, 89

Carbamates; Decarbamylation; Cholinesterase assay **240**, 107

Cell separation; B cells; Density perturbation; Lymphocytes; Peripheral blood mononuclear cells; T cells **240**, 187

Ceramides; Superoxide dismutase; Liposomes; Anti-inflammatory properties; Bioavailability **240**, 117

Cholesteryl ester transfer protein (CETP); Monoclonal antibody; ELISA; Synthetic peptide **240**, 1

Cholinesterase assay; Decarbamylation; Carbamates **240**, 107

Collagen crosslinks; Pyridinoline; Deoxypyridinoline; Ultra violet susceptibility **240**, 95

COPD; Asthma; Eosinophil cationic protein; Inhaled glucocorticosteroids; Local secretion; Myeloperoxidase; Plasma protein leakage; Sputum; Tryptase **240**, 163

Copper oxidation; LDL; Neuraminidase **240**, 221

0009-8981/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved

Coronary heart disease; Apolipoprotein B; Small dense low density lipoprotein particle; LDL Pattern B **240**, 63

Cortisol; Elastase inhibitory capacity; α-2-Macroglobulin; Hepatocellular carcinoma **240**, 179

Crohn's disease; Ulcerative colitis; Polymorphism; Glutathione *S*-transferase; Susceptibility **240**, 53

Cultured skin fibroblast; Galactosemia; Galactosemia variants; High performance liquid chromatography; Uridine diphosphate galactose; Uridine diphosphate glucose; Uridine; Galactose 1-phosphate uridyl transferase; Erythrocyte **240**, 21

Decarbamylation; Cholinesterase assay; Carbamates **240**, 107

Density perturbation; B cells; Cell separation; Lymphocytes; Peripheral blood mononuclear cells; T cells **240**, 187

Deoxypyridinoline; Collagen crosslinks; Pyridinoline; Ultra violet susceptibility **240**, 95

Elastase inhibitory capacity; α-2-Macroglobulin; Cortisol; Hepatocellular carcinoma **240**, 179

ELISA; Monoclonal antibody; Cholesteryl ester transfer protein (CETP); Synthetic peptide **240**, 1

Enalapril; Captopril; Hypertension; Red blood cells; Glutathione; Glutathione-dependent enzymes; Lipid peroxidation **240**, 89

Enzyme assay; Pyruvate dehydrogenase; Human mitochondria; Lactate dehydrogenase; Oxamate **240**, 129

Enzyme-linked immunosorbent assay; Tissue inhibitor of metalloproteinase-1; Matrix metalloproteinases; monoclonal antibody; Acute phase proteins **240**, 137

Eosinophil cationic protein; Asthma; COPD; Inhaled glucocorticosteroids; Local secretion; Myeloperoxidase; Plasma protein leakage; Sputum; Tryptase **240**, 163

Erythrocyte; Galactosemia; Galactosemia variants; High performance liquid chromatography; Uridine diphosphate galactose; Uridine diphosphate glucose; Uridine; Galactose 1-phosphate uridyl transferase; Cultured skin fibroblast **240**, 21

Galactose 1-phosphate uridyl transferase; Galactosemia; Galactosemia variants; High performance liquid chromatography; Uridine diphosphate galactose; Uridine diphosphate glucose; Uridine; Erythrocyte; Cultured skin fibroblast **240**, 21

Galactosemia; Galactosemia variants; High performance liquid chromatography; Uridine diphosphate galactose; Uridine diphosphate glucose; Uridine; Galactose 1-phosphate uridyl transferase; Erythrocyte; Cultured skin fibroblast **240**, 21

Galactosemia variants; Galactosemia; High performance liquid chromatography; Uridine diphosphate galactose; Uridine diphosphate glucose; Uridine; Galactose 1-phosphate uridyl transferase; Erythrocyte; Cultured skin fibroblast **240**, 21

Glucose monitoring; Interstitial fluid; Bio-sensor; Type II diabetes **240**, 11

Glutathione *S*-transferase; Ulcerative colitis; Crohn's disease; Polymorphism; Susceptibility **240**, 53

Glutathione; Captopril; Enalapril; Hypertension; Red blood cells; Glutathione-dependent enzymes; Lipid peroxidation **240**, 89

Glutathione-dependent enzymes; Captopril; Enalapril; Hypertension; Red blood cells; Glutathione; Lipid peroxidation **240**, 89

Hepatocellular carcinoma; Elastase inhibitory capacity; α-2-Macroglobulin; Cortisol **240**, 179

High performance liquid chromatography; Galactosemia; Galactosemia variants; Uridine diphosphate galactose; Uridine diphosphate glucose; Uridine; Galactose 1-phosphate uridyl transferase; Erythrocyte; Cultured skin fibroblast **240**, 21

Human mitochondria; Pyruvate dehydrogenase; Lactate dehydrogenase; Enzyme assay; Oxamate **240**, 129

5-Hydroxyindole-acetic acid clearance; Renal blood flow; Newborn rabbits **240**, 155

3-Hydroxyisovalerylcarnitine; 3-Methylcrotonyl CoA carboxylase; Acylcarnitine **240**, 35

Hypercholesterolaemia; Selenoprotein P; LDL-apheresis **240**, 209

Hypertension; Captopril; Enalapril; Red blood cells; Glutathione; Glutathione-dependent enzymes; Lipid peroxidation **240**, 89

Immunoblotting; Lipoprotein(a); Apolipoprotein(a); Phenotyping; Monoclonal **240**, 75

Inhaled glucocorticosteroids; Asthma; COPD; Eosinophil cationic protein; Local secretion; Myeloperoxidase; Plasma protein leakage; Sputum; Tryptase **240**, 163

Interstitial fluid; Glucose monitoring; Bio-sensor; Type II diabetes **240**, 11

Lactate dehydrogenase; Pyruvate dehydrogenase; Human mitochondria; Enzyme assay; Oxamate **240**, 129

Larynx carcinoma; Tartrate resistant acid phosphatase; Osteoclasts; Macrophages; Bone osteolysis **240**, 213

LDL; Copper oxidation; Neuraminidase **240**, 221

LDL Pattern B; Apolipoprotein B; Small dense low density lipoprotein particle; Coronary heart disease **240**, 63

LDL-apheresis; Selenoprotein P; Hypercholesterolaemia **240**, 209

Lipid peroxidation; Captopril; Enalapril; Hypertension; Red blood cells; Glutathione; Glutathione-dependent enzymes **240**, 89

Lipoprotein(a); Apolipoprotein(a); Phenotyping; Monoclonal; Immunoblotting **240**, 75

Liposomes; Superoxide dismutase; Ceramides; Anti-inflammatory properties; Bioavailability **240**, 117

Local secretion; Asthma; COPD; Eosinophil cationic protein; Inhaled glucocorticosteroids; Myeloperoxidase; Plasma protein leakage; Sputum; Tryptase **240**, 163

Lymphocytes; B cells; Cell separation; Density perturbation; Peripheral blood mononuclear cells; T cells **240**, 187

α-2-Macroglobulin; Elastase inhibitory capacity; Cortisol; Hepatocellular carcinoma **240**, 179

Macrophages; Tartrate resistant acid phosphatase; Larynx carcinoma; Osteoclasts; Bone osteolysis **240**, 213

Matrix metalloproteinases; Tissue inhibitor of metalloproteinase-1; Enzyme-linked immunosorbent assay; monoclonal antibody; Acute phase proteins **240**, 137

3-Methylcrotonyl CoA carboxylase; Acylcarnitine; 3-Hydroxyisovalerylcarnitine **240**, 35

Monoamine oxidase; Alzheimer's disease **240**, 99

Monoclonal; Lipoprotein(a); Apolipoprotein(a); Phenotyping; Immunoblotting **240**, 75

Monoclonal antibody; ELISA; Cholesteryl ester transfer protein (CETP); Synthetic peptide **240**, 1

Monoclonal antibody; Tissue inhibitor of metalloproteinase-1; Matrix metalloproteinases; Enzyme-linked immunosorbent assay; Acute phase proteins **240**, 137

Myeloperoxidase; Asthma; COPD; Eosinophil cationic protein; Inhaled glucocorticosteroids; Local secretion; Plasma protein leakage; Sputum; Tryptase **240**, 163

Neuraminidase; Copper oxidation; LDL **240**, 221

Newborn rabbits; 5-Hydroxyindole-acetic acid clearance; Renal blood flow **240**, 155

Osteoclasts; Tartrate resistant acid phosphatase;

Larynx carcinoma; Macrophages; Bone osteolysis **240**, 213

Oxamate; Pyruvate dehydrogenase; Human mitochondria; Lactate dehydrogenase; Enzyme assay **240**, 129

Peripheral blood mononuclear cells; B cells; Cell separation; Density perturbation; Lymphocytes; T cells **240**, 187

Phenotyping; Lipoprotein(a); Apolipoprotein(a); Monoclonal; Immunoblotting **240**, 75

Plasma protein leakage; Asthma; COPD; Eosinophil cationic protein; Inhaled glucocorticosteroids; Local secretion; Myeloperoxidase; Sputum; Tryptase **240**, 163

Polymorphism; Ulcerative colitis; Crohn's disease; Glutathione *S*-transferase; Susceptibility **240**, 53

Pyridinoline; Collagen crosslinks; Deoxypyridinoline; Ultra violet susceptibility **240**, 95

Pyruvate dehydrogenase; Human mitochondria; Lactate dehydrogenase; Enzyme assay; Oxamate **240**, 129

Red blood cells; Captopril; Enalapril; Hypertension; Glutathione; Glutathione-dependent enzymes; Lipid peroxidation **240**, 89

Renal blood flow; 5-Hydroxyindole-acetic acid clearance; Newborn rabbits **240**, 155

Selenoprotein P; Hypercholesterolaemia; LDL-apheresis **240**, 209

Small dense low density lipoprotein particle; Apolipoprotein B; LDL Pattern B; Coronary heart disease **240**, 63

Sputum; Asthma; COPD; Eosinophil cationic protein; Inhaled glucocorticosteroids; Local secretion; Myeloperoxidase; Plasma protein leakage; Tryptase **240**, 163

Superoxide dismutase; Liposomes; Ceramides; Anti-inflammatory properties; Bioavailability **240**, 117

Susceptibility; Ulcerative colitis; Crohn's disease; Polymorphism; Glutathione *S*-transferase **240**, 53

Synthetic peptide; Monoclonal antibody; ELISA; Cholesteryl ester transfer protein (CETP) **240**, 1

T cells; B cells; Cell separation; Density perturbation; Lymphocytes; Peripheral blood mononuclear cells **240**, 187

Tartrate resistant acid phosphatase; Larynx carcinoma; Osteoclasts; Macrophages; Bone osteolysis **240**, 213

Tissue inhibitor of metalloproteinase-1; Matrix metalloproteinases; Enzyme-linked immunosorbent assay; monoclonal antibody; Acute phase proteins **240**, 137

Tryptase; Asthma; COPD; Eosinophil cationic protein; Inhaled glucocorticosteroids; Local secretion; Myeloperoxidase; Plasma protein leakage; Sputum **240**, 163

Type II diabetes; Glucose monitoring; Interstitial fluid; Bio-sensor **240**, 11

Ulcerative colitis; Crohn's disease; Polymorphism; Glutathione *S*-transferase; Susceptibility **240**, 53

Ultra violet susceptibility; Collagen crosslinks; Pyridinoline; Deoxypyridinoline **240**, 95

Uridine; Galactosemia; Galactosemia variants; High performance liquid chromatography; Uridine diphosphate galactose; Uridine diphosphate glucose; Galactose 1-phosphate uridyl transferase; Erythrocyte; Cultured skin fibroblast **240**, 21

Uridine diphosphate galactose; Galactosemia; Galactosemia variants; High performance liquid chromatography; Uridine diphosphate glucose; Uridine; Galactose 1-phosphate uridyl transferase; Erythrocyte; Cultured skin fibroblast **240**, 21

Uridine diphosphate glucose; Galactosemia; Galactosemia variants; High performance liquid chromatography; Uridine diphosphate galactose; Uridine; Galactose 1-phosphate uridyl transferase; Erythrocyte; Cultured skin fibroblast **240**, 21